Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|October 4, 2023

Particle Measuring Systems Announce Acquisition of Environmental Monitoring Services Limited and EMS Particle Solutions

Author(s)Jill Murphy

EMS is a leader in the cleanroom industry, delivering complete cleanroom monitoring and control solutions, services to customers, and ensuring quality by design from inception to process control.

Particle Measuring Systems Inc. announced the acquisition of Environmental Monitoring Services and EMS Particle Solutions and their parent company on Oct. 2, 2023. According to the press release, EMS is a leader in the cleanroom industry, delivering complete cleanroom monitoring and control solutions, services to customers, and ensuring quality by design from inception to process control.

Particle Measuring Systems has experience in contamination monitoring and control for cleanrooms and aseptic manufacturing environments. Additionally, the acquisition aligns with Particle Measuring Systems’ strategy to be direct in every major geographical market to best support and service customers with advanced contamination monitoring and control solutions. Their partnership with EMS will last approximately 30 years as an exclusive sales and service channel for customers in these strategic territories.

“It has been gratifying to grow EMS over the last 30 years,” said Dave Nolan, managing director at EMS, in a press release. “This is an exciting and natural next step for our organization and I’m looking forward to continuing as part of this great team.”

“We are always looking for ways to provide our customers with better solutions while maintaining our strong growth trajectory and being recognized as an employer of choice by our employees,” said interim Particle Measuring Systems, Inc. President, Mark Fleiner, in a press release. “Acquiring EMS helps us achieve these goals while also preparing for continuity of service and solutions in this strategic geography.”

Source: Particle Measuring Systems (PDF press release)


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.